Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

bayer animal health gmbh - flumethrin - bistadestrip - 275 mg - bier

Den Europæiske Union - dansk - EMA (European Medicines Agency)

esteve pharmaceuticals gmbh - thiotepa - hematopoietic stem cell transplantation; neoplasms - antineoplastiske midler - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

accord healthcare b.v. - diazepam - tabletter - 5 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

alternova a/s - diazepam - tabletter - 2 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

alternova a/s - diazepam - tabletter - 5 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

vbi vaccines b.v. - hepatitis b overflade antigen - hepatitis b - vacciner - prehevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis b virus in adults. it can be expected that hepatitis d will also be prevented by immunisation with prehevbri as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection. the use of prehevbri should be in accordance with official recommendations.

Den Europæiske Union - dansk - EMA (European Medicines Agency)

dynavax gmbh - hepatitis b overflade antigen - hepatitis b - vacciner - heplisav b is indicated for the active immunisation against hepatitis b virus infection (hbv) caused by all known subtypes of hepatitis b virus in adults 18 years of age and older. the use of heplisav b should be in accordance with official recommendations. it can be expected that hepatitis d will also be prevented by immunisation with heplisav b as hepatitis d (caused by the delta agent) does not occur in the absence of hepatitis b infection.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm healthcare a/s - diazepam - tabletter - 2 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm healthcare a/s - diazepam - tabletter - 5 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - hepatitis b, rekombinant overflade antigen - hepatitis b; immunization - vacciner - 5 micrograms hbvaxpro is indicated for active immunisation against hepatitis-b-virus infection caused by all known subtypes in individuals from birth through 15 years of age considered at risk of exposure to hepatitis-b virus. den specifikke risiko-kategorier, der skal være vaccineret, skal der fastlægges på grundlag af de officielle anbefalinger. det kan forventes, at hepatitis d-virusset vil også forebygges ved vaccination med hbvaxpro som hepatitis d (forårsaget af delta-agent) ikke forekommer i mangel af hepatitis b infektion. 10 micrograms hbvaxpro is indicated for active immunisation against hepatitis-b-virus infection caused by all known subtypes in individuals 16 years of age or more considered at risk of exposure to hepatitis-b virus. den specifikke risiko-kategorier, der skal være vaccineret, skal der fastlægges på grundlag af de officielle anbefalinger. det kan forventes, at hepatitis d-virusset vil også forebygges ved vaccination med hbvaxpro som hepatitis d (forårsaget af delta-agent) ikke forekommer i mangel af hepatitis b infektion. 40 micrograms hbvaxpro is indicated for the active immunisation against hepatitis-b-virus infection caused by all known subtypes in predialysis and dialysis adult patients. det kan forventes, at hepatitis d-virusset vil også forebygges ved vaccination med hbvaxpro som hepatitis d (forårsaget af delta-agent) ikke forekommer i mangel af hepatitis b infektion.